Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH continued access study for participants transitioning from ViiV parent HIV treatment studies
PACTR202603833394781Phase 3Not yet recruiting
- Sponsor
- ViiV Healthcare
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Planned start May 2026; status: not yet recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202603833394781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603833394781.